Floatz Rating
CCC54/100
Confidence
Indicative
Sponsor
Rambam Health Care Campus
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05753657CT.gov A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer. | — | Recruiting | — | — | — |
NCT04123067CT.gov Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke | — | Terminated | — | — | — |
NCT00426413CT.gov Ketosis Prone Diabetes in African-Americans | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hyperglycemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pioglitazone (this asset) | Rambam Health Care Campus | P1/2 | CCC · 54 |
| Metformin | The First Affiliated Hospital of Xiamen University | P4 | BBB |
| Saffron | Birjand University of Medical Sciences | P4 | BB |
| Olanzapine | Washington University School of Medicine | P4 | BB |
| Capecitabine | Brigham and Women's Hospital | P4 | BB |
| Exenatide | Saint Luke's Health System | P4 | BB |
| Sitagliptin | Dawn Smiley MD | P4 | BB |
| Risperidone | Nathan Kline Institute for Psychiatric Research | P4 | BB |
| Losartan | Brigham and Women's Hospital | P4 | BB |
+26 more in the Hyperglycemia cohort
Other indications for Pioglitazone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetes Mellitus | — | P4 | BBB · 79 |
| Metabolic Dysfunction-Associated Steatohepatitis | — | P4 | BBB · 75 |
| Abdominal Obesity-Metabolic Syndrome | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pioglitazone in Hyperglycemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pioglitazone-hyperglycemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →